Russian pharma production booming, anticipating third wave of pandemic

20 April 2021

Russian pharmaceutical production is booming, according to latest statistics provided by some leading analyst agencies in the field of pharmaceutics and local media reports.

According to data of RNC Pharma agency, in January-February 2021 of the current year, production grew by 61% in value terms compared to the same period last year and reached 101.4 billion roubles ($1.32 billion).

Nikolay Bespalov, development director of RNC Pharma, said in an interview with Russian Lenta business paper, such a growth was mainly due to the effect of low base, as manufacturers are now ramping up production in anticipation of the third wave of coronavirus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK